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Abstract
We have recently demonstrated that histone deacetylase inhibitor, Vorinostat, applied as a single therapy or in combination
with caspase-8 downregulation exhibits high anti-tumoral activity on endometrial carcinoma cell lines. In the present study,
we have assessed the signalling processes underlying anti-tumoral effects of Vorinostat. Increasing evidence suggests that
reactive oxygen species are responsible for histone deacetylase inhibitor-induced cell killing. We have found that Vorinostat
induces formation of reactive oxygen species and DNA damage. To investigate the role of oxidative stress as anti-neoplastic
mechanism, we have evaluated the effects of different antioxidants (Bha, Nac and Tiron) on endometrial carcinoma cell line
Ishikawa treated with Vorinostat. We show that Bha, Nac and Tiron markedly inhibited the cytotoxic effects of Vorinostat,
increasing cell viability in vitro. We found that all three antioxidants did not inhibited accumulation of acetyl Histone H4, so
that antioxidants did not inhibit Vorinostat activity. Finally, we have evaluated the effects of antioxidants on anti-tumoral
activity of Vorinostat as monotherapy or in combination with caspase-8 downregulation in vivo. Interestingly, antioxidants
blocked the reduction of tumour growth caused by Vorinostat, but they were unable to inhibit anti-tumoral activity of
Vorinostat plus caspase-8 inhibition.
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Introduction
Histone deacetylase (HDAC) and histone acetyltransferase
(HAT) are a class of enzymes which regulate the acetylation
status of histones and non-histone proteins, the most frequently
post-translational epigenetic modification in eukaryotic cells [1,2].
Histone tails are normally positively charged due to amine groups.
These positive charges help them to interact with and bind to the
negatively charged phosphate groups on the DNA backbone.
HATs induce protein acetylation that neutralizes the positive
charges on the histone by changing amines into amides decreasing
the ability of the histones to bind to DNA. This allows chromatin
expansion and gene transcription. HDACs induce protein
hypoacetylation increasing positive charge of histone tails causing
compaction of the DNA/histone complex and preventing
expression of genes required for cell cycle arrest and apoptosis
[3–7]. Aberrant protein acetylation, mostly on histones, has been
related to cancer while anomalous expression of HDACs has been
found in large types of cancer [8,9]. One of the most promising
groups of anticancer agents is the inhibitors of histone deacetylases
(HDACis), that lead to an accumulation of acetylated proteins
both in tumor and normal cells [10–12]. Therefore, HDACi have
been found to suppress migration and invasion, cause growth
arrest, differentiation, and apoptosis in a broad types of cancers
such as thyroid [13,14], breast [15,16], colon [17,18], endometrial
[19,20], ovary [20],lung [21,22] and others by altering the
transcription of a small number of genes [9–12],[23]. A recent
study of our laboratory has demonstrated that HDACi such as
Vorinostat can also be effective for inducing apoptotic cell death in
endometrial cancer (EC) cells [19]. In this previous work, we have
demonstrated that Vorinostat displays anti-neoplastic activity on
EC cells alone or in combination with inhibition of caspase-8.
Several mechanisms underlying anti-neoplastic activity of
Vorinostat have been proposed, including induction of apoptotic
pathways, cell growth arrest, autophagy, mitotic catastrophe, or
senescence [24–26]. Some of these processes such as apoptosis or
cell growth are affected by multiple intracellular events, including
the production of reactive oxygen species (ROS) [24–26].
Increasing lines of evidence demonstrate that, in addition to their
effects on histone acetylation and epigenetic regulation, produc-
tion of ROS may participate in anti-tumoral activity of HDACis.
Recent studies suggest that HDACis might cause cell death by the
induction of ROS such as superoxide, hydroxyl radical and
hydrogen peroxide as determined by DCF dye oxidation assay in a
large variety of cancers [27–30]. Along with ROS generation,
DNA damage has usually been observed during the process of cell
death [31,32]. These two phenomena, the increase of ROS level
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and DNA damage, can be found either independent or one being
caused by the other one [33].
In the present study, we have investigated the mechanisms by
which Vorinostat exerts its anti-tumoral activity on EC. We have
concentrated the study on the effects of Vorinostat on ROS
production and we have analysed whether ROS production high
oxidative stress is involved in cytotoxic effects of Vorinostat alone
or in combination with caspase-8 inhibition.
Materials and Methods
Cell Lines, Culture Conditions and Transfection
The Ishikawa 3-H-12 cell line (IK) was obtained from the
American Type Culture Collection (Manassas, VA). EC cells were
grown in Dulbecco’s modified Eagle’s medium (Sigma, St. Louis,
MO) supplemented with 10% fetal bovine serum (Invitrogen, Inc.,
Carlsbad, CA), 1 mmol/L HEPES (Sigma), 1 mmol/L sodium
pyruvate (Sigma), 2 mmol/L L-glutamine (Sigma), and 1% of
penicillin/streptomycin (Sigma) at 37uC with saturating humidity
and 5% CO2.
Chemical reagents
Vorinostat (suberoylanilide hydroxamic acid) was obtained from
Merck. A 50 mM stock was prepared in dimethylsulphoxide
(DMSO) and stored at 280uC. 2,5- diphenyl tetrazolium bromide
assay (MTT), DMSO, bis-benzimide fluorescent dye (Hoechst
33258), Butylated hydroxyanisole (BHA; tert-butyl-4-hydroxyani-
sole), N-Acetyl Cysteine (Nac), Sodium 4,5-dihydroxybenzene-1,3-
disulfonate (Tiron), Vitamin C, Rodamine 123 (Rh123), fluores-
cent probe CM-H2DCFDA, DHE (D7008-10 mg) and monoclo-
nal antibody to Tubulin were from Sigma (St Louis, MO, USA).
Cell Viability Assays and Assessment of Apoptosis
The general mitochondrial activity of EC cell lines was
determined by assaying reduction of MTT (3-(4, 5-dimethylthia-
zol-2-yl)-2, 5 diphenyltetrazolium bromide) to formazan. EC cells
were plated on M96-well plates at 156103 cells per well. After the
indicated treatments, cells were incubated for 30 minutes with
0.5 mg/ml of MTT reagent and lysed with dimethylsulphoxide
(DMSO) to dissolve the blue formazan crystals produced by the
mitochondrial succinate dehydrogenase of the living cells. Cell
viability proportionate to optical density was measured using a
colorimetric assay of mitochondria activity. Drug resistance was
represented as the percentage of live cells surviving after drug
treatment relative to control cells. Absorbance were measured
using a spectrophotometer (Bio-Rad, Richmond, CA, U.S.A.) at a
dual wavelength of 595 nm and 620 nm.
Apoptotic cells were identified by nuclear staining with bis-
benzimide fluorescent dye (Hoechst 33258), after the indicated
treatments, to a final concentration of 0.5 mg/ml to each M24
well. Cells were counted under epifluorescence microscope (Leica
Microsystems, Wetzlar, Germany).
Clonogenic assay
EC cells were seeded onto 6-well plates at a density of 16103
cells per dish. On the next day, cells were treated for 24 hours,
after that period of time mediums were changed and they were
incubated for 12–14 days. The colonies were stained with MTT
(1/10) for 30 minutes and fixed in methanol for 5 minutes and
maintained in 2 mL PBS. Colonies consisting of .50 cells were
scored using the Quantity One program (Colony Counting Quick
Guide) and two replicate dishes were counted for each treatment.
Western Blot Analysis
The EC cell lines was washed with cold phosphate-buffered
saline (PBS) and lysed with lysis buffer (2% sodium dodecyl sulfate,
125 mmol/L Tris-HCl, pH 6.8). Protein concentrations were
determined with a protein assay kit (Bio-Rad, Hercules, CA).
Equal amounts of proteins were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride membranes (Millipore). Nonspecific
binding was blocked by incubation with TBST (20 mmol/L
Tris-HCl, pH 7.4, 150 mmol/L NaCl, 0.1% Tween-20) plus 5%
of nonfat milk. Membranes were incubated with the primary
antibodies overnight at 4uC. Signal was detected with ECL
Advance (Amersham-Pharmacia, Buckinghamshire, UK). The
antibodies used were: active caspase-3 and caspase-9 were
obtained from Cell-Signal (Beverly, MA), active caspase-8
(monoclonal, Calbiochem), anti-phospho-Histone H2A.X
(Ser139) (monoclonal, Millipore), phosphor-38 (Thr180/Tyr182)
(polyclonal, Calbiochem), Anti-p38 MAPKinse (pThr 180, pTyr
182) (polyclonal, Calbiochem), p21 (monoclonal, Cell-Signal), p27
(monoclonal, Cell-Signal), a-tubulin (monoclonal, Sigma) and
anti-Acetyl-Histone H4 (Lys12) (polyclonal, Cell-Signal) were used
as a Vorinostat control.
Membranes were then incubated with peroxidase-coupled anti-
mouse or anti-rabbit secondary antibodies (Amersham-Pharmacia
Uppsala, Sweden) for 1 h, followed by chemiluminescent detection
with ECL Advance (Amersham Pharmacia, Buckinghamshire,
UK).
The acetyl histone H4 band intensities were calculated and
normalized to Tubulin intensities using Image Lab 4.0.1. Lane
and Bands Quantity Analysis Tools.
Measurements of intracellular reactive oxygen species
(ROS)
Dichorofluorescein diacetate (DCFH-DA) was used to assess
levels of net intracellular generation of ROS and dihydroethidium
(DHE), was used to determine levels of superoxide anion (.O2
2).
DCFH-DA is a peroxidesensitive fluorescent probe that is
nonpolar and diffuses into the cell. Intracellular esterases cleave
the diacetate ester group and entrap the polar, nonfluorescent
DCFH within the cell. ROS can oxidize this substance to the
fluorescent compound DCF. As a positive control, IK cells were
incubated with hydrogen peroxide (H2O2) (1 mM) for 30 min
prior to the lost their ability to entrap the DCFH-DA dye and
convert it to the membrane impermeable form DCF (a function of
their intracellular esterase activity). Cells were treated with
Vorinostat for the indicated times, washed twice in PBS,
tripsinized and 66106 ml cells were incubated in PBS containing
20 mM DCFH-DA or 10 mM DHE for 30 min prior to ROS
measurement. The fluorescence of the cell population is propor-
tional to the levels of intracellular ROS generated, and was
measured with a FACScan (Becton Dickinson, Mountain View,
CA, USA) at 588 nm emission.
Immunofluorescence and quantification of cH2AX
After indicated doses of treatment, IK cells were maintained at
37uC and 5%CO2 until fixation at 24 hours post-treatment. Cells
were washed twice with phosphate-buffered saline (PBS), fixed for
20 min with 4% paraformaldehyde, permeabilized with methanol
during 5 min, washed and maintained with PBS. After blocking
(5% HS +5% FBS +0,2% Glicina +0,1% Trito´ in PBS) during 1 h,
cells were incubated overnight at 4uC with a monoclonal anti-
cH2AX antibody (monoclonal, Millipore), anti-Acetyl-Histone H4
(Lys12) (polyclonal, Cell-Signal) 1:500 in PBS, and washed and
Antioxidants Block Vorinostat Cytotoxicity
PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e92764
Figure 1. Vorinostat induces DNA damage and production of ROS in IK cell line. A) Representative images (left) and quantification (right) of
cH2AX immunofluorescence of IK cells showing foci formation after Vorinostat treatment. **p,0.001 compared with the control group. B) Ik cells
were treated with the indicated doses of Vorinostat and cell lysates were subjected to western blot using antibodies anti-acetylated H4, anti-H2AX
(Ser-139) and antitubulin. C) Quantification of ROS production determined by staining with DCFH-DA and quantified by flow cytometer (Left graph).
D) Loss of mitochondrial membrane potential (MMP) was determined by staining with Rhodamine 123 and quantified by flow cytometer (Right
graph). An absence of Rho123 from cells indicated the loss of MMP (DYm). **p,0.001 compared with the control group. E) Quantification of ROS
production on cells treated with Vorinostat or Vorinostat plus the anti-oxidant NaC. **p,0.001 compared with the control group.
doi:10.1371/journal.pone.0092764.g001
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incubated with FITClabeled secondary antibody (Sigma) 1:500 in
PBS in the dark for 1 h at room temperature. Cells were then
washed, counterstained, and stained with bis-benzimide fluores-
cent dye (Hoechst 33258), to a final concentration of 0.5 mg/ml,
in the dark for 35 minutes. Cells were counted under epifluores-
cence microscope (Leica Microsystems, Wetzlar, Germany).
Aleatory sampling methods were used to select the images and
all the cells in each selected image were screened. The cH2AX foci
per nucleus were counted by eye. Cells were judged as ‘‘positive’’
for cH2AX foci if they displayed 10 or more discrete dots of
brightness. For quantitation of foci, a minimum of 300 cells were
analysed for each time point.
Xenografting and Vorinostat/Nac administration
Immunodeficient female SCID hr/hr mice (age, 12 weeks;
weight 20–25 g) were maintained in Specific Pathogen Free (SPF)
conditions. Animals were subcutaneously injected with HEC-1A
Figure 2. Effects of Nac, Tiron and Bha on reduction of cell viability caused by Vorinostat. A) IK cells were treated with 3 mM Vorinostat,
alone or in combination with increasing doses of Nac, Tiron and Bha. Cell viability was assessed by MTT assay 24 h after treatment. Results are
expressed as percent of viability. B) Quantification of Hoechst-stained apoptotic nuclei of IK cells was realized 24 h after being treated with
Vorinostat, Vorinostat plus antioxidants or left untreated. Results are expressed as percent of the control values.
doi:10.1371/journal.pone.0092764.g002
Figure 3. Nac treatment reduces DNA damage and ROS production in IK endometrial cell line. A) Representative cH2AXimmuno-
fluorescence corresponding to IK cells after the combination of Vorinostat and Nac treatment at indicated time. Cells were stained with Hoechst to
evidence nuclei. B). Quantifification of the number of cells exhibiting cH2AX positive focis. **p,0.001 compared with the control group C) IK cells
were treated with Vorinostat plus Nac, at indicate doses, or left untreated for 24 h. Cell lysates were subjected to western blot with, anti-H2AX (Ser-
139) and anti-Tubulin.
doi:10.1371/journal.pone.0092764.g003
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cells (1,56106) suspended in 100 ml PBS+Matrigel (1:1). Tumors
were allowed to growth for 38 days. Xenografted mice were
treated with an intraperitoneal injection of Vorinostat at 50 mg/
kg/day and with or without Nac 250 mg/kg/day for 5 days/week
during two consecutive weeks. Tumors were measured weekly
with calipers. Tumor size was calculated using the formula: Tumor
weight (TW, mg) = (D*d2)/2 = mm3.
Results
Vorinostat induces ROS production and DNA damage on
endometrial cancer cells
We have recently demonstrated that Vorinostat is an effective
anti-neoplastic agent for EC cell lines [19]. Here, we have
investigated the molecular mechanisms of anti-neoplastic effects of
Vorinostat. Since Vorinostat is an HDAC inhibitor, we first
investigated the ability of Vorinostat to cause DNA damage on the
EC cell line IK. For this purpose, we measured Vorinostat-
induced cH2AX foci formation by immunofluorescence micros-
copy (Fig 1A). Vorinostat caused a significant increase of nuclear
cH2AX foci 24 hours after treatment. In control IK cells, the
number of foci per nucleus averaged 24.5% and increased to
65.4% and 78.7% after treatment with 1 mM or 3 mM,
respectively. Increased phosphorylation of cH2AX was further
confirmed by western blot analysis of IK cells treated with
Vorinostat for 24 hours (Fig 1B). These findings suggest that
Vorinostat caused double strand DNA breaks on IK cells.
Previous studies have suggested that the lethal effect of HDACis
could be related to oxidative stress as measured by the increase of
ROS levels [27–30]. Generation of ROS in IK cells was
monitored during the treatment with Vorinostat at different
concentrations (1 and 3 mM) (Fig 1C). ROS concentration was
substantially increased in Vorinostat treated cells. Such increase
correlated with a loss of membrane potential (MMP) (as measured
by Rho123 staining) (Fig 1D). These results indicate that
Vorinostat treatment results in increased of oxidative stress in
IK cells.
Finally, to demonstrate specific production of ROS after
Vorinostat treatment, IK cells were exposed to 5 mM Nac plus
3 mM Vorinostat for 24 h. These IK cells were harvested for the
determination of ROS production. To evaluate the general
profiles of ROS production in these cells, CM-H2DCFDA was
used in the assays for the detection of intracellular superoxide,
hydrogen peroxide, and other ROS. The co-treatment of IK cells
with Nac alleviated Vorinostat-induced ROS production, com-
pared with single-agent treatment (Fig 1E). IK cells treated for
30 min with H2O2 were assumed as positive control.
Antioxidants inhibit the cytotoxic effects and the
apoptotic features induced by Vorinostat treatment
Once demonstrated that ROS production is involved in
Vorinostat-induced DNA damage on EC cells, we sought to
investigate their role in anti-neoplastic activity of Vorinostat. For
this purpose, we first tested the effects of three different
antioxidants (Nac, Bha and Tiron) on the decrease in cell viability
caused by Vorinostat treatment. IK cell line was treated with
Vorinostat 3 mM plus increasing doses of the three antioxidants
and cell viability was assessed by MTT assay 24 h after treatment.
The results showed that all three antioxidants caused a dose-
dependent inhibition of Vorinostat cytotoxicity (Fig 2A). We also
addressed the effects of Nac, Bha and Tiron on apoptotic nuclear
morphology caused by Vorinostat. For this purpose, IK cells were
treated with 3 mM Vorinostat, alone or in the presence of 5 mM
Nac, 300 mM Bha and 5 mM Tiron for 24 hours. Cells were
stained with Hoechst and the number of nuclei displaying
apoptotic morphology was evaluated. Addition of Nac dramati-
cally reduced the number of nuclei displaying apoptotic morphol-
ogy in the cultures treated with Vorinostat (Fig 2B). Addition of
Bha and Tiron also reduced the number of apoptotic cells,
although these two antioxidant were less effective than Nac
(Fig2B). Because Nac displayed highest efficiency in reducing pro-
apoptotic effects of Vorinostat, we chose it for subsequent
experiments.
Collectively, these findings indicate that ROS production
caused by Vorinostat plays a significant functional role in the
enhanced lethality induced by Vorinostat treatment.
Co-administration of Nac and Vorinostat reduces DNA
damage and ROS production
To evaluate the effects of Nac in Vorinostat-induce DNA
damage, we determined the number of cH2AX foci in IK cells
upon co-treatment with Nac plus Vorinostat. The number of cells
displaying focis in their nucleus was dramatically decreased in cell
cultures co-treated with Vorinostat plus Nac (Fig A, 3B). As shown
in Figure 3B, the induction of cH2AX in IK cell line was observed
after 24 h, indicating an evident potentiation by Vorinostat-
induced DNA damage. In contrast, cotreatment of IK cells with
Nac plus Vorinostat results in a decrease of H2AX phosphory-
Figure 4. Effect of co-treatment with Vorinostat and antioxi-
dants on histone acetylation. Representative western blot showing
acetylated histone H4 and tubulin western blot analysis of IK cells
treated or left untreated with 3 mM Vorinostat, IK cells treated with
indicated doses of Nac, Tiron and Bha antioxidants and finally, IK cells
treated with Vorinostat together with antioxidants at indicated doses
for 24 hours. Mean and standard deviations of the ratios of intensities of
Ac-histone H4 band-Tubulin bands from the corresponding lanes.
doi:10.1371/journal.pone.0092764.g004
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lation (Fig 3C). These findings indicate that treatment of IK cells
with Vorinostat potently induces DNA damage associated with
caspase-dependent activation of the apoptotic program. Collec-
tively, these findings suggest that oxidative injury plays a
significant functional role in lethality induced the Vorinostat in
IK cancer cells.
Antioxidants do not impair Vorinostat-induced Acetyl-H4
accumulation
We have previously reported that antioxidants can block the
activity of antineoplastic drugs by interfering with their mechanism
of action [34]. Because antioxidants markedly reduced DNA
damage and ROS production, we hypothesized that antioxidants
could be affecting the ability of Vorinostat to modify histone
acetylation. To rule out this possibility, we monitored histone H4
Figure 5. Nac treatment increases colony formation and reduces caspase-3 cleavage in IK endometrial cancer cells treated with
Vorinostat. A) IK cells were seeded as a single-cell suspension with a specified number of cells. After allowing cells time to attach (6 h), Vorinostat
plus Nac or the vehicle control was added and treated for indicated times. Ten to fourteen days after seeding, survival curves (from counting the
number of colonies) were generated after normalizing. *p,0.05, **p,0.001 compared with the control group. B) IK cells were treated with Vorinostat
and Nac, at indicate doses, or left untreated (UN) for 24 h. Cell lysates were subjected to western blot with Acetylate H4, anti-caspase-3, 8 and anti-
Tubulin.
doi:10.1371/journal.pone.0092764.g005
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acetylation after co-treatment of IK cells with Vorinostat plus
antioxidants. To ensure that Vorinostat treatment was effective
when we administrated antioxidants, we first examined the
accumulation of Acetyl H4 by Western Blot. Accumulation of
Acetyl H4 results from the histone hyperacetylation caused by the
activity of HDACi. IK cells treated with Nac, Bha or Tiron plus
Vorinostat, showed similar amounts of Acetylated H4 products to
those observed in cells treated with Vorinostat alone (Figure 4A, B
and C, see lanes 2 and 4). These results demonstrate that
antioxidants do not impair the molecular mechanism of Vorino-
stat’s action.
Co-treatment with Nac and Vorinostat increased the
colony capacity and reduced the cleavage of caspase-3
Once demonstrated that antioxidants reduced ROS production
and DNA damage without interfering with acetylation of histones,
we investigated the effects of Nac on con clonogenic capability and
apoptosis of IK cells treated with Vorinostat. Combination of
Vorinostat plus Nac treatment resulted in a significant increase of
colony cells exhibiting surviving fractions over cultures treated
with Vorinostat alone (p-value = 3,956* 1025) (Fig 5A). Western
blot analysis (Fig 5B) revealed that co-administration of Vorinostat
and Nac resulted in a decrease in caspase-3 processing. These
Figure 6. Nac treatment do not reduce the effects of blocking caspase-8 and Vorinostat treatment in IK cancer cell line. A) IK cells
were infected with lentiviruses carrying Caspase-8 shRNA (FSV-Casp-8 shRNA) or vehicle control (FSV) and treated with 3 mM Vorinostat plus 5 mM
Nac at indicated times. The graph represents a quantification of nuclei displaying nuclear apoptotic morphology. B) Western blot analysis of whole
lysates from IK cells infected with lentiviruses carrying Caspase-8 shRNA (FSV-Casp-8 shRNA) or vehicle control (FSV). The membranes were reproved
with Acetyl H4, Caspase-8, Caspase-3 and Tubulin to ensure equal protein loading.
doi:10.1371/journal.pone.0092764.g006
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results suggest that Nac co-treatment reduces Vorinostat-induced
cell death and clonogenic ability, suggesting that ROS production
was plays a critical role in mediating anti-tumoral effects of
Vorinostat.
Nac treatment does not inhibit antineoplastic effects of
Vorinostat plus caspase-8 inhibition
We have recently demonstrated that combination of Vorinostat
and caspase-8 exhibits high anti-neoplastic activity on EC cells in
vivo and in vitro. Therefore, we wondered whether antioxidants
could also block the anti-tumoral effects of caspase-8 inhibition
plus Vorinostat combination. For this purpose, IK cells were
infected with lentiviruses carrying caspase-8 shRNA and were
treated with 3 mM Vorinostat alone or in combination with 5 mM
Nac for 24 h. After that period of time we counted the number of
cells displaying apoptotic morphology. Interestingly, Nac treat-
ment did not reduce the number of apoptotic cells when caspase-8
was downregulated (Fig 6A). Accordingly, Western Blot analysis
revealed that caspase-3 processing was not reduced after Nac
Figure 7. Nac treatment impairs Vorinostat but not Vorinostat plus caspase-8 inhibition effects on endometrial cancer. Tumour
weight (TW) measuraments and representative images corresponding to tumours developed by IK cells infected with lentiviruses carrying control
vector (FSV) or caspase-8 shRNA (FSV-Casp8 shRNA) and subcutaneously grafted in SCID mice. At day 42, mice were divided into four groups, and
were untreated (with vehicle) or injected intraperitoneally with Nac alone (250 mg/kg/day), Vorinostat alone (50 mg/kg/day) or Vorinostat plus Nac.
Graphs (A) In the presence of caspase-88, Nac blocks anti-tumor effect of Vorinostat (B). In the absence of caspase-8, Nac does not block anti-tumor
effect of Vorinostat.
doi:10.1371/journal.pone.0092764.g007
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treatment when caspase-8 was inhibited. These data indicates that,
anti-tumoral action of caspase-8 inhibition plus Vorinostat
treatment is insensitive to antioxidants.
Nac impairs anti-tumoral activity of Vorinostat, but not
anti-tumoral effects of Vorinostat plus caspase-8
inhibition
Finally, we assessed the effects of antioxidants on therapeutic
potential of Vorinostat or Vorinostat plus caspase-8 inhibition in
vivo. For this purpose, IK cells were infected with lentiviruses
containing control shRNA (FSV) or caspase-8 shRNA (FSV-
Caspase-8) and were xenotransplanted; tumors were allowed to
growth for 42 days. At this point, mice were divided in four
groups: first group was left untreated (injected with vehicle), a
second group was injected with Nac alone, the third group was
injected with Vorinostat alone and the last group was injected with
Nac and one hour after with Vorinostat. This treatment was
applied daily during two weeks (see material and methods for
protocol of administration). Tumor size and animal weight was
measured weekly from the first day of cell injection to the end of
the protocol. As we show in Figure 7A, administration of
Vorinostat plus Nac led to development of tumours displaying
similar size to that observed in control (without treatment) mice.
These results indicate that, as we observed in vitro, antioxidants also
block anti-tumoral effects of Vorinostat in vivo. In contrast, the
same experiment performed with IK cells with downregulated
caspase-8 had a different outcome. In this case, tumors from
Vorinostat or Vorinostat plus Nac treated mice had similar
reduction over non treated mice (Fig 7A), indicating that
antioxidants are unable to block the effects of Vorinostat plus
caspase-8 combination of EC cells (Fig 7B).
Discussion
The main goal of this study was to address the molecular
mechanisms underlying anti-tumoral activity of the HDACi,
Vorinostat. We have recently demonstrated that Vorinostat has
a marked anti-tumoral activity on endometrial cancer cells, bothin
vitro and in vivo [19]. In this previous work, we demonstrated that
Vorinostat induced cell growth arrest, loss of clonogenic capability
and apoptosis of EC cells. In the present study, we have addressed
the molecular mechanisms of anti-tumoral activity of Vorinostat.
Our results demonstrate that Vorinostat treatment causes
anincrease of ROS production, DNA damage and, inhibition of
ROS production by addition of antioxidants dramatically reduces
anti-neoplastic effects of Vorinostat.
Epigenetic deregulations is currently considered a hallmark of
cancer [35]. Initially, the rationale for HDACi usage as
chemotherapeutic agents was based on the observation that
epigenetic deregulation was common alteration in human cancers.
However, HDAC action is not restricted to the regulation of
histone acetylation status, but rather regulate the acetylation status
of other cytosolic or nuclear proteins that, in turn, regulate many
cellular processes [36]. During the last years, several studies have
evidenced that tumoricidal activity of HDACi goes beyond
epigenetic regulation. Several molecular mechanisms have been
proposed as mediators of anti-tumoral effects of HDACi, one of
such is the generation of ROS. Our results demonstrate that EC
cells show a marked increase of ROS production upon Vorinostat
treatment. Although it is assumed that HDACi induces the
production of ROS, the effect of addition of antioxidants on
cellular outcome is still controversial. Some studies have demon-
strated that inhibition of cellular antioxidant response sensitizes
resistant leukemia cells lines to HDACis [37]. Accordingly,
addition of antioxidants impairs HDACi cytotoxicity in acute
myelogenous leukemia cells [31,32] or colon cancer cells [38]. In
contrast, other studies have demonstrated that antioxidants
enhance anti-tumoral effects of HDACi on prostate cancer [39]
or melanoma cells [40]. To this regard the role of antioxidants in
cancer prevention and cancer therapy is still debated. From one
hand, an increasing number of evidences support a cancer
preventive role of antioxidants; on the other hand, antioxidants
may alter or modify the efficacy of chemotherapeutic treatments
[41]. Our in vitro and in vivo results demonstrate that reduction
ROS levels by antioxidants results in a marked reduction of anti-
tumoral activity of Vorinostat, supporting that ROS production
has an important role in driving cytotoxic effects of Vorinostat in
EC cells.
We have also found that ROS production correlates with
increased phosphorylation of H2AX. H2AX is phosphorylated on
Ser139 by ATM kinase in response to DNA damage-induced DNA
double-strand breaks and is one of the earliest events in the DNA
damage signaling and repair [42]. Vorinostat-induced DNA
damage can come from two sources: it can be caused by
production of ROS or, it also be independently caused by
modification of DNA repair activity and chromatin remodeling
factors [33]. Because we have observed that H2AX phosphory-
lation caused by Vorinostat is reduced by antioxidant treatment, it
is likely that phosphorylation of H2AX is consequence, at least in
part, of a DNA damage caused by Vorinostat-induced ROS
production.
As we mentioned above, our previous results demonstrated that
combinatory therapy using Vorinostat and inhibition of Caspase-8
had additive anti-tumoral effects on EC cells in vivo. Here, we have
also studied the role of ROS on such effects. Interestingly,
antioxidants failed to block reduction of tumoral growth caused by
combination of Vorinostat plus caspase-8 downregulation. This
result suggests that combination of such treatments is able to
override the effects of antioxidants. One possibility to explain such
results is that combination of caspase-8 inhibition and Vorinos-
tatactivate alternative mechanisms of tumoral growth inhibition
that are independent of ROS production. Another possible
explanation is that inhibition of capase-8 impair antioxidant
efficacy to block ROS activity. Nevertheless, we think that the fact
of combination Vorinostat with Caspase-8 inhibition displays
tumoricidal activity regardless of oxidative stress status enhances
its value as possible treatment for endometrial cancer.
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